Forte Biosciences, Inc. is a biopharmaceutical company, which engages in the provision of dermatology products and services. The company is headquartered in Dallas, Texas and currently employs 14 full-time employees. The company went IPO on 2017-04-13. The company is advancing clinical development of FB102 into patient-based trials for celiac disease and non-segmental vitiligo. The firm's FB102 program focuses on addressing key pathways implicated in these indications with a CD122 antagonist. CD122 is a subunit of IL-2/IL-15 receptors which are key regulators of NK cells and certain T cell subsets. FB102 has potentially other autoimmune and autoimmune-related applications including vitiligo, alopecia areata, and type 1 diabetes (T1D). Its subsidiaries include Forte Subsidiary, Inc. and Forte Biosciences Australia Proprietary Limited.
Dr. Paul Wagner is the Chairman of the Board of Forte Biosciences Inc, joining the firm since 2020.
What is the price performance of FBRX stock?
The current price of FBRX is $44.22, it has increased 0.68% in the last trading day.
What are the primary business themes or industries for Forte Biosciences Inc?
Forte Biosciences Inc belongs to Biotechnology industry and the sector is Health Care
What is Forte Biosciences Inc market cap?
Forte Biosciences Inc's current market cap is $905.6M
Is Forte Biosciences Inc a buy, sell, or hold?
According to wall street analysts, 6 analysts have made analyst ratings for Forte Biosciences Inc, including 3 strong buy, 8 buy, 1 hold, 0 sell, and 3 strong sell